13F Holdings
中文EN

AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 2023311 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.9%
TTM net income YoY-4.8%
TTM EPS YoY2.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin86.2%
Operating margin—
Net margin-417.0%
FCF margin-347.9%
EBITDA margin—

Returns

ROE-394.7%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets—
Debt / equity29.72x
Current ratio1.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio—
Payout ratio—
Capex / revenue20.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20242024-12-31 · USDFY20232023-12-31 · CNYFY20222022-12-31 · CNY
Income statement
Revenue$134.35M221.98M209.71M
Cost of revenue$3.98M30.54M22.00M
Gross profit$130.36M191.44M187.71M
R&D expense$129.77M706.97M743.10M
Interest expense$8.83M96.06M52.78M
Pretax income-$54.15M-932.86M-887.17M
Income tax$1.43M-7.15M-4.25M
Net income-$55.54M-925.64M-882.92M
EPS (basic)-0.18-3.28-3.35
EPS (diluted)-0.18-3.28-3.35
Balance sheet
Cash & equivalents$122.35M1.04B1.35B
Receivables$11.39M145.89M—
Inventory$904,00016.17M—
Current assets$201.96M1.34B—
PP&E, net$116.37M905.82M—
Goodwill$3.38M24.69M—
Total assets———
Current liabilities$159.82M934.17M—
Short-term debt$106.73M616.40M—
Long-term debt$121.85M1.18B—
Total debt$228.58M1.80B—
Total liabilities$321.08M2.43B—
Shareholders' equity$36.19M60.42M408.66M
Net debt$106.23M757.55M—
Shares outstanding315.22M290.20M—
Cash flow statement
Operating cash flow-$15.26M-726.08M-653.91M
Capital expenditure$3.33M46.11M203.29M
Free cash flow-$18.58M-772.18M-857.20M
Investing cash flow-$49.60M21.92M-384.61M
Financing cash flow$43.12M368.75M619.27M
Stock-based compensation$2.87M31.50M22.11M
Share buybacks—5.92M26.78M

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.